DOCSLIB.ORG

Calmodulin and Calmodulin-Dependent Protein Kinase II Inhibit Hormone Secretion in Human Parathyroid Adenoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Calmodulin and Calmodulin-Dependent Protein Kinase II Inhibit Hormone Secretion in Human Parathyroid Adenoma 31 Calmodulin and calmodulin-dependent protein kinase II inhibit hormone secretion in human parathyroid adenoma Ming Lu1,2,3, Erik Berglund1, Catharina Larsson1,3, Anders Ho¨o¨g4, Lars-Ove Farnebo1 and Robert Bra¨nstro¨m1 1Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital L1:03, SE-171 76 Stockholm, Sweden 2Department of Geriatric Endocrinology, First Affiliated Hospital of Guangxi Medical University, NanNing, People’s Republic of China 3Center for Molecular Medicine (CMM), Karolinska University Hospital, SE-171 76 Stockholm, Sweden 4Department of Oncology–Pathology, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden (Correspondence should be addressed to M Lu at Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital; Email: [email protected]) Abstract 2C 2C Intracellular calcium ([Ca ]i) is the most relevant modulator adenoma cells in spite of increased [Ca ]i. The inhibitory C of parathyroid hormone (PTH) secretion. Uniquely, an effect of Ca2 calmodulin on PTH secretion may be due to 2C increase in [Ca ]i results in an inhibition of PTH secretion, the absence of synaptotagmin 1 protein in parathyroid and it probably exerts its function via calcium-binding protein adenomas, as demonstrated by western blot analysis. An pathways. The ubiquitous calcium-binding proteins, calmo- increased extracellular calcium level acutely lowered the dulin and calmodulin-dependent protein kinase II (CaMKII), amount of active phosphorylated CaMKII (pCaMKII) in have well-established roles in regulated exocytosis in neurons adenoma cells in vitro, indicating the physiological importance and neuroendocrine cells. However, their roles in parathyroid of this pathway. Moreover, a negative correlation between the cells and PTH secretion are still unclear. Using reverse levels of pCaMKII in parathyroid adenomas and serum transcription-PCR and western blot analysis, we have calcium was found in 20 patients with primary hyper- demonstrated the expression of calmodulin and CaMKII in parathyroidism. Taken together, these results show that human normal parathyroid and parathyroid chief cell calmodulin negatively contributes to the regulation of PTH adenomas. Blocking of calmodulin and CaMKII activity by secretion in parathyroid adenoma, at least partially via a the specific antagonists calmidazolium and KN-62 respect- CaMKII pathway. ively caused a rise in PTH secretion from parathyroid Journal of Endocrinology (2011) 208, 31–39 2C Introduction In addition to that, the mechanism behind [Ca ]i increase and PTH inhibition remains unclear. The parathyroid glands are important organs for calcium Calmodulin is a calcium-binding protein involved in 2C regulation in the human body. Parathyroid cells sense small the sensing of increased [Ca ]i concentrations and subse- changes in serum calcium levels and adjust parathyroid quent signal transduction to a variety of cellular targets. hormone (PTH) secretion to keep serum calcium within a Calmodulin-dependent protein kinase II (CaMKII) is a narrow range. In this sense, parathyroid cells are unique calmodulin-binding protein participating in functions such as 2C 2C 2C because intracellular Ca ([Ca ]i) inhibits PTH secretion, exocytosis, [Ca ]i oscillation, and ion-channel activation instead of stimulating secretion as in other endocrine cell (Wang 2008). Calmodulin is ubiquitously expressed and has types (Shoback et al. 1983). The calcium-sensing receptor been detected in both normal and pathological parathyroid (CaSR) is a G-protein-coupled receptor located in the cell (Brown et al. 1981). However, a correlation between levels of 2C membrane. Upon binding of extracellular calcium ([Ca ]e) calmodulin expression, calcium sensitivity, and PTH to CaSR, a phospholipase C–inositol triphosphate pathway is secretion has not been demonstrated (Brown et al. 1981, 2C activated, resulting in several fold increase in [Ca ]i and Oldham et al. 1982). Expression of CaMKII has also been 2C subsequent inhibition of PTH secretion. [Ca ]i has been reported in hyperfunctioning human parathyroid cells established as the central second messenger for PTH secretion where modulation of CaMKII activity was found to be (Shoback et al. 1984), involving, e.g. the PLA2-AA and the calcium and calmodulin dependent (Kinder et al. 1987, Kato MAP kinase pathways (Kifor et al. 2001, Almaden et al. 2002). et al. 1991). However, the interaction between calcium, Journal of Endocrinology (2011) 208, 31–39 DOI: 10.1677/JOE-10-0123 0022–0795/11/0208–031 q 2011 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/24/2021 10:54:46PM via free access 32 MLUand others . Calmodulin and CaMKII in parathyroid adenomas calmodulin, and CaMKII in human parathyroid has not several transcript variants due to alternative splicing. Primers been clarified. In this study, we have investigated the were designed based on the common sequence of each gene; relationship between calmodulin and CaMKII activity and therefore, it does not identify specific transcript variants. PTH secretion. The PCR reactions were performed in 20 ml reactions with amplification conditions as follows: initial denaturation for 2 min at 94 8C, followed by 40 cycles of 30 s at 95 8C, 30 s at 50–55 8C, and 1 min at 68 8C. Human brain cDNA Materials and Methods (Invitrogen, Cat. no. B1110033) was used as a positive control. The PCR products were subsequently size verified by agarose Parathyroid tissue samples gel electrophoresis and were observed and photographed Normal parathyroid tissue and parathyroid adenomas were under u.v. light. Tofurther verify the quality,all PCR products collected with informed consent and ethical approval at the were purified using a PCR purification kit (Qiagen, Cat. Karolinska University Hospital, Sweden. Histopathological no. Q28104) and were sequenced with the assistance of the diagnoses were according to the WHO classification (DeLellis KISeq core facility at Karolinska Institutet, Stockholm, Sweden. et al. 2004). Histopathological examination of representative sections verified a high tumor cell content of the analyzed Western blot analysis tissue samples. Twenty previously published parathyroid chief cell adenomas and one normal parathyroid biopsy specimen (Lu et al. 2008) Reverse transcription-PCR were used for western blot analysis (No. 1–20, Table 2), using The reverse transcription (RT)-PCR analysis included previously described methodology (Lu et al. 2008). Total previously published samples of one normal parathyroid proteins were extracted using 1% NP-40 lysis buffer supplied ( Juhlin et al. 2010), and four or more parathyroid adenoma with protease inhibitors, and then quantified with a Bio-Rad samples (Lu et al. 2010) for each gene analyzed. Total RNA protein assay. Following separation by SDS–PAGE, proteins was extracted using TRIzol reagent (Invitrogen), purified by were blotted onto nitrocellulose membranes and incubated DNAse I (Amplification Grade, Invitrogen), and quantified overnight at 4 8C with primary antibodies, followed by by spectrophotometry. Total RNA (3 mg) from each sample appropriate secondary antibodies. The following primary was reverse transcribed into 40 ml cDNA using the Super- antibodies and dilutions were applied: monoclonal rabbit Script III First-Strand Synthesis System for RT-PCR anti-calmodulin that targets the single calmodulin protein (Invitrogen, Cat. no. 18080-051). In all, 2 ml of each cDNA commonly encoded by the CALM1, CALM2, and CALM3 were used for amplification of calmodulin 1, 2, and 3 genes genes (EP799Y, Abcam, Cambridge, UK, Cat. no. ab45689) (CALM1, CALM2, and CALM3) and of CaMKII a, b, g, at dilution 1:1000; polyclonal anti-endogenous CaMKII and d genes (CAMK2A, CAMK2B, CAMK2G,and antibody that detects total CaMKII a and b subunits levels CAMK2D) with the Platinum Taq DNA polymerase high- (Acris, Herford, Germany, Cat. No. AP02774PU-S) at 1:500; fidelity kit (Invitrogen). Gene-specific forward and reverse polyclonal anti-CaMKIIp-Thr286 antibody specific for the PCR primers (Table 1) were designed in house according to phosphorylated form of CaMKII a and b subunits published genomic data and PCR primer design guidelines. (pCaMKII, Acris, Cat. no. AP2526PU-S) at 1:800; mono- CAMK2A, CAMK2B, CAMK2G, and CAMK2D have clonal anti-synaptotagmin 1 antibody (SYSY, Goettingen, Table 1 Details and primers used for reverse transcription-PCR of the CALM1–3 and CAMK2A, CAMK2B, CAMK2G, and CAMK2D genes Gene Gene Protein Primer Amplicon Annealing symbol location product orientation Primer sequence (50–30) length (bp) temperature (8C) CALM1 14q24–q31 Calmodulin Forward CAGATATTGATGGAGACGGA 629 51 Reverse GAGCACACGAAGTACAAGAG CALM2 2p21 Calmodulin Forward GACAAAGATGGTGATGGAAC 394 51 Reverse GTCTTCACTTTGCTGTCATC CALM3 19q13.2 Calmodulin Forward ACAAGGATGGAGATGGCAC 313 57 Reverse ATCTCATCCACCTCCTCATC CAMK2A 5q32 CaMKII a subunit Forward ACCAGCTCTTCGAGGAATTG 241 56 Reverse GTGACCAGGTCGAAGATCAG CAMK2B 7p14.3 CaMKII b subunit Forward GAGAGAGAGGCTCGGATCTG 395 56 Reverse TGTCCACAGGCTTGCCATAC CAMK2G 10q22 CaMKII g subunit Forward GACTTCTGAAACATCCAAAC 431 55 Reverse CACCAGGAGGATATACAGGA CAMK2D 4q26 CaMKII d subunit Forward TAGCAAATCCAAGGGAGCAG 377 55 Reverse ATGGGTGCTTCAGTGCCTC Journal of Endocrinology (2011) 208, 31–39 www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/24/2021 10:54:46PM via free access Calmodulin and CaMKII
Load more

Recommended publications
  • Supplemental Information to Mammadova-Bach Et Al., “Laminin Α1 Orchestrates VEGFA Functions in the Ecosystem of Colorectal Carcinogenesis”
    Supplemental information to Mammadova-Bach et al., “Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinogenesis” Supplemental material and methods Cloning of the villin-LMα1 vector The plasmid pBS-villin-promoter containing the 3.5 Kb of the murine villin promoter, the first non coding exon, 5.5 kb of the first intron and 15 nucleotides of the second villin exon, was generated by S. Robine (Institut Curie, Paris, France). The EcoRI site in the multi cloning site was destroyed by fill in ligation with T4 polymerase according to the manufacturer`s instructions (New England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Site directed mutagenesis (GeneEditor in vitro Site-Directed Mutagenesis system, Promega, Charbonnières-les-Bains, France) was then used to introduce a BsiWI site before the start codon of the villin coding sequence using the 5’ phosphorylated primer: 5’CCTTCTCCTCTAGGCTCGCGTACGATGACGTCGGACTTGCGG3’. A double strand annealed oligonucleotide, 5’GGCCGGACGCGTGAATTCGTCGACGC3’ and 5’GGCCGCGTCGACGAATTCACGC GTCC3’ containing restriction site for MluI, EcoRI and SalI were inserted in the NotI site (present in the multi cloning site), generating the plasmid pBS-villin-promoter-MES. The SV40 polyA region of the pEGFP plasmid (Clontech, Ozyme, Saint Quentin Yvelines, France) was amplified by PCR using primers 5’GGCGCCTCTAGATCATAATCAGCCATA3’ and 5’GGCGCCCTTAAGATACATTGATGAGTT3’ before subcloning into the pGEMTeasy vector (Promega, Charbonnières-les-Bains, France). After EcoRI digestion, the SV40 polyA fragment was purified with the NucleoSpin Extract II kit (Machery-Nagel, Hoerdt, France) and then subcloned into the EcoRI site of the plasmid pBS-villin-promoter-MES. Site directed mutagenesis was used to introduce a BsiWI site (5’ phosphorylated AGCGCAGGGAGCGGCGGCCGTACGATGCGCGGCAGCGGCACG3’) before the initiation codon and a MluI site (5’ phosphorylated 1 CCCGGGCCTGAGCCCTAAACGCGTGCCAGCCTCTGCCCTTGG3’) after the stop codon in the full length cDNA coding for the mouse LMα1 in the pCIS vector (kindly provided by P.
    [Show full text]
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Coupling of Autism Genes to Tissue-Wide Expression and Dysfunction of Synapse, Calcium Signalling and Transcriptional Regulation
    PLOS ONE RESEARCH ARTICLE Coupling of autism genes to tissue-wide expression and dysfunction of synapse, calcium signalling and transcriptional regulation 1 2,3 4 1,5 Jamie ReillyID *, Louise Gallagher , Geraldine Leader , Sanbing Shen * 1 Regenerative Medicine Institute, School of Medicine, Biomedical Science Building, National University of a1111111111 Ireland (NUI) Galway, Galway, Ireland, 2 Discipline of Psychiatry, School of Medicine, Trinity College Dublin, Dublin, Ireland, 3 Trinity Translational Medicine Institute, Trinity Centre for Health SciencesÐTrinity College a1111111111 Dublin, St. James's Hospital, Dublin, Ireland, 4 Irish Centre for Autism and Neurodevelopmental Research a1111111111 (ICAN), Department of Psychology, National University of Ireland (NUI) Galway, Galway, Ireland, a1111111111 5 FutureNeuro Research Centre, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland a1111111111 * [email protected] (JR); [email protected] (SS) Abstract OPEN ACCESS Citation: Reilly J, Gallagher L, Leader G, Shen S Autism Spectrum Disorder (ASD) is a heterogeneous disorder that is often accompanied (2020) Coupling of autism genes to tissue-wide with many co-morbidities. Recent genetic studies have identified various pathways from expression and dysfunction of synapse, calcium hundreds of candidate risk genes with varying levels of association to ASD. However, it is signalling and transcriptional regulation. PLoS ONE unknown which pathways are specific to the core symptoms or which are shared by the co- 15(12): e0242773. https://doi.org/10.1371/journal. pone.0242773 morbidities. We hypothesised that critical ASD candidates should appear widely across dif- ferent scoring systems, and that comorbidity pathways should be constituted by genes Editor: Nirakar Sahoo, The University of Texas Rio Grande Valley, UNITED STATES expressed in the relevant tissues.
    [Show full text]
  • Profiling Data
    Compound Name DiscoveRx Gene Symbol Entrez Gene Percent Compound Symbol Control Concentration (nM) JNK-IN-8 AAK1 AAK1 69 1000 JNK-IN-8 ABL1(E255K)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317I)-nonphosphorylated ABL1 87 1000 JNK-IN-8 ABL1(F317I)-phosphorylated ABL1 100 1000 JNK-IN-8 ABL1(F317L)-nonphosphorylated ABL1 65 1000 JNK-IN-8 ABL1(F317L)-phosphorylated ABL1 61 1000 JNK-IN-8 ABL1(H396P)-nonphosphorylated ABL1 42 1000 JNK-IN-8 ABL1(H396P)-phosphorylated ABL1 60 1000 JNK-IN-8 ABL1(M351T)-phosphorylated ABL1 81 1000 JNK-IN-8 ABL1(Q252H)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(Q252H)-phosphorylated ABL1 56 1000 JNK-IN-8 ABL1(T315I)-nonphosphorylated ABL1 100 1000 JNK-IN-8 ABL1(T315I)-phosphorylated ABL1 92 1000 JNK-IN-8 ABL1(Y253F)-phosphorylated ABL1 71 1000 JNK-IN-8 ABL1-nonphosphorylated ABL1 97 1000 JNK-IN-8 ABL1-phosphorylated ABL1 100 1000 JNK-IN-8 ABL2 ABL2 97 1000 JNK-IN-8 ACVR1 ACVR1 100 1000 JNK-IN-8 ACVR1B ACVR1B 88 1000 JNK-IN-8 ACVR2A ACVR2A 100 1000 JNK-IN-8 ACVR2B ACVR2B 100 1000 JNK-IN-8 ACVRL1 ACVRL1 96 1000 JNK-IN-8 ADCK3 CABC1 100 1000 JNK-IN-8 ADCK4 ADCK4 93 1000 JNK-IN-8 AKT1 AKT1 100 1000 JNK-IN-8 AKT2 AKT2 100 1000 JNK-IN-8 AKT3 AKT3 100 1000 JNK-IN-8 ALK ALK 85 1000 JNK-IN-8 AMPK-alpha1 PRKAA1 100 1000 JNK-IN-8 AMPK-alpha2 PRKAA2 84 1000 JNK-IN-8 ANKK1 ANKK1 75 1000 JNK-IN-8 ARK5 NUAK1 100 1000 JNK-IN-8 ASK1 MAP3K5 100 1000 JNK-IN-8 ASK2 MAP3K6 93 1000 JNK-IN-8 AURKA AURKA 100 1000 JNK-IN-8 AURKA AURKA 84 1000 JNK-IN-8 AURKB AURKB 83 1000 JNK-IN-8 AURKB AURKB 96 1000 JNK-IN-8 AURKC AURKC 95 1000 JNK-IN-8
    [Show full text]
  • Bioinformatic Analyses in Early Host Response To
    Schroyen et al. BMC Genomics (2016) 17:196 DOI 10.1186/s12864-016-2547-z RESEARCH ARTICLE Open Access Bioinformatic analyses in early host response to Porcine Reproductive and Respiratory Syndrome virus (PRRSV) reveals pathway differences between pigs with alternate genotypes for a major host response QTL Martine Schroyen1†, Christopher Eisley2†, James E. Koltes3, Eric Fritz-Waters1, Igseo Choi4, Graham S. Plastow5, Leluo Guan5, Paul Stothard5, Hua Bao5, Arun Kommadath5, James M. Reecy1, Joan K. Lunney4, Robert R. R. Rowland6, Jack C. M. Dekkers1 and Christopher K. Tuggle1* Abstract Background: AregiononSus scrofa chromosome 4 (SSC4) surrounding single nucleotide polymorphism (SNP) marker WUR10000125 (WUR) has been reported to be strongly associated with both weight gain and serum viremia in pigs after infection with PRRS virus (PRRSV). A proposed causal mutation in the guanylate binding protein 5 gene (GBP5)is predicted to truncate the encoded protein. To investigate transcriptional differences between WUR genotypes in early host response to PRRSV infection, an RNA-seq experiment was performed on globin depleted whole blood RNA collectedon0,4,7,10and14dayspost-infection(dpi)from eight littermate pairs with one AB (favorable) and one AA (unfavorable) WUR genotype animal per litter. Results: Gene Ontology (GO) enrichment analysis of transcripts that were differentially expressed (DE) between dpi across both genotypes revealed an inflammatory response for all dpi when compared to day 0. However, at the early time points of 4 and 7dpi, several GO terms had higher enrichment scores compared to later dpi, including inflammatory response (p <10-7), specifically regulation of NFkappaB (p < 0.01), cytokine, and chemokine activity (p <0.01).At10and 14dpi, GO term enrichment indicated a switch to DNA damage response, cell cycle checkpoints, and DNA replication.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Serial Analysis of Gene Expression in Normal P53 Null Mammary Epithelium
    Oncogene (2002) 21, 6366 – 6376 ª 2002 Nature Publishing Group All rights reserved 0950 – 9232/02 $25.00 www.nature.com/onc Serial analysis of gene expression in normal p53 null mammary epithelium C Marcelo Aldaz*,1, Yuhui Hu1, Rachael Daniel1, Sally Gaddis1, Frances Kittrell2 and Daniel Medina2 1The University of Texas M.D. Anderson Cancer Center, Department of Carcinogenesis, Smithville, Texas, TX 78957, USA; 2Baylor College of Medicine Department of Molecular and Cellular Biology, Houston, Texas, TX 77030, USA Much evidence has accumulated implicating the p53 gene function although activating mutations were also as of importance in breast carcinogenesis. However, observed. Usually p53 abnormalities associate with much still remains to be uncovered on the specific poorer clinical outcome. This, likely, is the consequence downstream pathways influenced by this important of the known critical roles of p53 in regulating the cell activator/repressor of transcription. This study investi- cycle, apoptosis, DNA repair and maintaining genome gated the effects of a p53 null genotype on the stability (Levine, 1997). The loss of wild type p53 transcriptome of ‘normal’ mouse mammary epithelium function is clearly an important event in breast using a unique in vivo model of preneoplastic transforma- tumorigenesis as documented both in human and murine tion. We used SAGE for the comparative analysis of p53 systems (Donehower et al., 1995; Elledge and Allred, wild type (wt) and null mammary epithelium unexposed 1994). However, the exact mechanisms by which such and exposed to hormonal stimulation. Analysis of the lack of normal gene function leads to cancer formation hormone exposed samples provided a comprehensive view and progression are only beginning to be understood.
    [Show full text]
  • Versão Do Arquivo Anexado / Version of Attached File: Versão Do Editor / Published Version
    UNIVERSIDADE ESTADUAL DE CAMPINAS SISTEMA DE BIBLIOTECAS DA UNICAMP REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP Versão do arquivo anexado / Version of attached file: Versão do Editor / Published Version Mais informações no site da editora / Further information on publisher's website: https://physoc.onlinelibrary.wiley.com/doi/full/10.14814/phy2.12409 DOI: 10.14814/phy2.12409 Direitos autorais / Publisher's copyright statement: ©2015 by John Wiley & Sons. All rights reserved. DIRETORIA DE TRATAMENTO DA INFORMAÇÃO Cidade Universitária Zeferino Vaz Barão Geraldo CEP 13083-970 – Campinas SP Fone: (19) 3521-6493 http://www.repositorio.unicamp.br Physiological Reports ISSN 2051-817X ORIGINAL RESEARCH Expression of calcium-buffering proteins in rat intrinsic laryngeal muscles Renato Ferretti1, Maria Julia Marques2, Tejvir S. Khurana3 & Humberto Santo Neto2 1 Departamento de Anatomia, Instituto de Biociencias de Botucatu, Universidade Estadual Paulista, Botucatu, Sao~ Paulo, Brazil 2 Departamento de Biologia Estrutural e Funcional, Instituto de Biologia, Universidade Estadual de Campinas, Campinas, Sao~ Paulo, Brazil 3 Department of Physiology, Perelman School of Medicine and Pennsylvania Muscle Institute, University of Pennsylvania, Philadelphia, Pennsylvania Keywords Abstract Calcium, laryngeal muscles, Ncx, Pmca1, Serca, store-operated calcium entry. Intrinsic laryngeal muscles (ILM) are highly specialized muscles involved in phonation and airway protection, with unique properties that allow them to Correspondence perform extremely rapid contractions and to escape from damage in muscle Humberto Santo Neto, Departamento de dystrophy. Due to that, they may differ from limb muscles in several physio- Biologia Estrutural e Funcional, Instituto de logical aspects. Because a better ability to handle intracellular calcium has been Biologia, Universidade Estadual de Campinas suggested to explain ILM unique properties, we hypothesized that the profile (UNICAMP).
    [Show full text]
  • Gene Expression Signatures and Biomarkers of Noninvasive And
    Oncogene (2006) 25, 2328–2338 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ORIGINAL ARTICLE Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics GM Nagaraja1, M Othman2, BP Fox1, R Alsaber1, CM Pellegrino3, Y Zeng2, R Khanna2, P Tamburini3, A Swaroop2 and RP Kandpal1 1Department of Biological Sciences, Fordham University, Bronx, NY, USA; 2Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA and 3Bayer Corporation, West Haven, CT, USA We have characterized comprehensive transcript and Keywords: representational difference analysis; micro- proteomic profiles of cell lines corresponding to normal arrays; proteomics; breast carcinoma; biomarkers; breast (MCF10A), noninvasive breast cancer (MCF7) and copper homeostasis invasive breast cancer (MDA-MB-231). The transcript profiles were first analysed by a modified protocol for representational difference analysis (RDA) of cDNAs between MCF7 and MDA-MB-231 cells. The majority of genes identified by RDA showed nearly complete con- Introduction cordance withmicroarray results, and also led to the identification of some differentially expressed genes such The transformation of a normal cell into a cancer cell as lysyl oxidase, copper transporter ATP7A, EphB6, has been correlated to altered expression of a variety of RUNX2 and a variant of RUNX2. The altered transcripts genes (Perou et al., 2000; Becker et al., 2005). The identified by microarray analysis were involved in cell–cell expression of some of these genes is a direct result of or cell–matrix interaction, Rho signaling, calcium home- sequence mutation, whereas other changes occur due to ostasis and copper-binding/sensitive activities.
    [Show full text]
  • Novel Insights Into Neuronal CAMK2 Function
    Novel Insights Novel UITNODIGING voor het bijwonen van de openbare verdediging into Neuronal CAMK2 Function CAMK2 Neuronal into van het proefschrift Novel Insights into Neuronal CAMK2 Function door Martijn J. Kool op dinsdag 11 december 2018 om 13:30 Professor Queridozaal Onderwijscentrum Erasmus MC Dr. Molewaterplein 40 3015 CD Rotterdam MARTIJN KOOL Moutersteeg 11 3024 RG Rotterdam Novel Insights [email protected] into Neuronal PARANIMFEN CAMK2 Function Thomas Hulst Martijn J. Kool [email protected] Laura-anne Grimbergen [email protected] Martijn J. Kool 15932-kool-cover.indd 1 22/10/2018 09:38 NOVEL INSIGHTS INTO NEURONAL CAMK2 FUNCTION Martijn Jacob Kool COLOFON Cover design: Front: "Hippocampus and CAMK2" by Jan Berkelouw Back: "Two Pyramidals" by Greg Dunn Layout: Design Your Thesis, www.designyourthesis.com Printing: Ridderprint B.V., www.ridderprint.nl ISBN: 978-94-6375-178-0 Copyright © 2018 by Martijn Jacob Kool. All rights reserved. Any unauthorized reprint or use of this material is prohibited. No part of this thesis may be reproduced, stored or transmitted in any form or by any means, without written permission of the author or, when appropriate, of the publishers of the publications. NOVEL INSIGHTS INTO NEURONAL CAMK2 FUNCTION NIEUWE INZICHTEN IN DE FUNCTIE VAN NEURONAAL CAMK2 PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof.dr. R.C.M.E. Engels en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op 11 december 2018 om 13:30 uur door Martijn Jacob Kool geboren te Rotterdam PROMOTIECOMMISSIE Promotor: Prof.dr.
    [Show full text]
  • Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in Vitro and in Vivo
    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Genetik Characterization of the Small Molecule Kinase Inhibitor SU11248 (Sunitinib/ SUTENT in vitro and in vivo - Towards Response Prediction in Cancer Therapy with Kinase Inhibitors Michaela Bairlein Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzender: Univ. -Prof. Dr. K. Schneitz Prüfer der Dissertation: 1. Univ.-Prof. Dr. A. Gierl 2. Hon.-Prof. Dr. h.c. A. Ullrich (Eberhard-Karls-Universität Tübingen) 3. Univ.-Prof. A. Schnieke, Ph.D. Die Dissertation wurde am 07.01.2010 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 19.04.2010 angenommen. FOR MY PARENTS 1 Contents 2 Summary ................................................................................................................................................................... 5 3 Zusammenfassung .................................................................................................................................................... 6 4 Introduction .............................................................................................................................................................. 8 4.1 Cancer ..............................................................................................................................................................
    [Show full text]